← Browse by Condition
Medical Condition
recurrent gliosarcoma
Total Trials
2
Recruiting Now
2
Trial Phases
Phase 2, Phase 1
ClinicalMetric tracks all active clinical trials for recurrent gliosarcoma sourced from ClinicalTrials.gov. Each listing includes the NCT identifier, current recruitment status, phase, primary endpoints, sponsor, estimated enrollment, and participating countries — updated daily as new studies open and status changes.
- Recruiting trials currently enrolling participants, with eligibility criteria and age requirements
- Phase 1–4 studies from early safety trials to post-marketing surveillance
- NIH, pharmaceutical sponsor, and academic medical center studies worldwide
- AI-powered plain-language summary available for every trial listing
Trial Phases
Phase 1 1
Phase 2 1
Top Sponsors
1 trial
1 trial
Recruiting Clinical Trials
NCT05465954 Phase 2
Recruiting
Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma
Enrollment
54 pts
Location
United States
Sponsor
Mayo Clinic
NCT03896568 Phase 1
Recruiting
MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma
Enrollment
36 pts
Location
United States
Sponsor
M.D. Anderson Cancer Center
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology